Company intelligence / Profile preview
NeuroTrauma Sciences
Alpharetta, Georgia, United Statesneurotraumasciences.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
NeuroTrauma Sciences has commenced first-in-human dosing in the US of their investigational neuroprotective drug NTS-104[1]. The company is developing therapies that address the underlying biological processes involved in the pathophysiological injury cascade associated with acute ischemic stroke and chronic stroke[3].
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaboration with Antwerp University Hospital, Belgium to support "CENTER-TBI" research[2]
Beyond the preview
Go deeper on NeuroTrauma Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroTrauma Sciences.